Baseline Assessment - Multiple Myeloma

0.25 AMA PRA Category 1 Credit(s) ™, 0.25 ANCC Contact Hours
Launch Date:
March 31, 2020
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Nurse Practitioners, Physician Assistants, Pharmacists, Oncology Nurses

Relevant Terms:

Multiple Myeloma

This baseline assessment is designed to assess learners' knowledge of key clinical concepts in multiple myeloma.

Pamela B. Dudkiewicz, DNP, APRN-BC, AOCNP

Pamela B. Dudkiewicz, DNP, APRN-BC, AOCNP
Nurse Practitioner
University of Miami Sylvester Comprehensive Cancer Center
Tampa, FL

Pamela Dudkiewicz, DNP, ARNP, AOCNP is a Nurse Practitioner working in the area of Hematology/Oncology at University of Miami Sylvester Comprehensive Cancer Center. She received her Bachelor’s of Science in Nursing from Florida International University in 1989, her Master’s of Science in Nursing from the University of Miami in 1998, and received her Doctor of Nursing Practice from Florida Atlantic University in 2013.

Pamela began working with the University of Miami Sylvester Comprehensive Cancer Center Department of Hematology in 2003. She attained her Advanced Oncology Certified Nurse Practitioner certification in 2004. She won Nurse Practitioner of the Year in 2016. She has been an active member in the Miami-Dade Chapter of the Oncology Nursing Society and serving on their board of directors for the past several years and most recently served as President for 2017. She is on several speaker bureaus and has been invited to speak at national and international conferences. She has published and co-published several peer-reviewed journal articles. Pamela has a passion for hematology and a true devotion for her patients. In her spare time, she loves to read, cycle and spend time with her family and 3 dogs.

Karolina Faysman, AOCNP

Karolina Faysman, AOCNP
UCLA Graduate School of Nursing Clinical Preceptor
Lead Hematology/Oncology Nurse Practitioner
Los Angeles, CA

Karolina Faysman, AOCNP graduated with BSN from CalState LA in 1999 and MSN/NP from UCLA in 2002. She has been working at UCLA in hematological malignancies and cellular department since 1999, initially as a staff nurse and later, in 2002 as a nurse practitioner.  Mrs. Faysman has been a national speaker since 2008 and a guest lecturer in graduate school of nursing at UCLA since 2006.  In addition, she actively precepts graduate students as well as medical students. Mrs. Faysman has been a sub-investigator in multiple clinical trials.

Teresa Fogaren, MSN, AGNP-C, OCN

Teresa Fogaren, MSN, AGNP-C, OCN
Hematology Nurse Practitioner
Tufts Medical Center
Boston, MA

Teresa Fogaren, MSN, AGNP-C, OCN is an recognized expert in the care of multiple myeloma and amyloidosis patients with over 30 years in practice as a hematology oncology nurse.  She is currently the nurse practitioner in the John C. Davis Amyloid and Myeloma program at Tufts Medical Center.  Over her career, she has honed numerous skills, including her keen clinical and procedural expertise.  She has served as a research nurse and coordinator which has made her an exceptional nurse practitioner in the care and management of patients on clinical trials. She is viewed as the “go to” person in the amyloid and myeloma practice at Tufts Medical Center and is well known for her generosity and willingness to share her knowledge with the entire interdisciplinary team

Amie Fonder, PA-C

Amie Fonder, PA-C
Physician Assistant
Mayo Clinic
Rochester, MN

Amie Fonder, PA-C received her Bachelor in Chemistry from the University of WI, River Falls in 2010. She completed her Masters in Physician Assistant Studies from the University of WI, La Crosse in 2015 and has been working as an outpatient hematology PA specializing in plasma cell disorders since. She enjoys teaching the next generation of advanced practice providers through precepting students and speaking at educational conferences.

Tiffany Richards, PhD, ANP-BC, AOCNP


Tiffany Richards, PhD, ANP-BC, AOCNP
Nurse Practitioner
University of Texas, MD Anderson Cancer Center
Houston, TX


Ms. Tiffany Richards is an adult nurse practitioner at the University of Texas MD Anderson Cancer Center in Houston. She received her master’s degree in nursing from the University of Wisconsin in Madison. Her primary research interest includes targeted therapies for patients with multiple myeloma (MM). Ms. Richards has given numerous presentations on MM and has been published in journals such as Multidisciplinary Cancer Care and The Myeloma Messenger. She is also an active member of the Oncology Nursing Society and International Myeloma Foundation.

Kevin Brigle, PhD, NP

Oncology Nurse Practitioner Massey Cancer Center

 Virginia Commonwealth University

Kevin has served as an Oncology Nurse Practitioner in the Hematological Malignancies Clinic at the Virginia Commonwealth University Massey Cancer Center in Richmond VA. He earned his Bachelor’s degree in Biology from the University of Dayton and his PhD in Molecular Microbiology from Virginia Tech. Following completion of his dissertation, he took a position as a postdoctoral fellow and later as Laboratory Director in the Division of Hematology and Oncology at Virginia Commonwealth University. While consulting on an NIH-funded grant in the School of Nursing, he completed the Nurse Practitioner Program at VCU. Following 1 year of practice as an Acute Care Nurse Practitioner in Internal Medicine, he came to his current position in the Hematological Malignancies Clinic at the Massey Cancer Center. The majority of his patient population includes those patients having myeloma or leukemia. In addition to his clinical role, He is an Adjunct Faculty in the School of Nursing and has authored or co-authored 29 peer-reviewed journal articles and 6 book chapters.
Kevin has served on a speakers bureau for AbbVie, Amgen, AstraZencea, Celgene, Incyte, Karyopharm, Sanofi, and Takeda.

Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN



Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN


Nurse Practitioner and Nurse Scientist

Cleveland Clinic Department of Hematology and Medical Oncology

Cleveland, OH

Dr. Beth Faiman began her nursing career at the Cleveland Clinic in 1994 as a nursing assistant. She received a bachelor of science in nursing and registered nurse certification at Ursuline College in Pepper Pike, Ohio in 1996. She received a master of science in nursing and certification as an adult nurse practitioner at Kent State University in Kent, Ohio in 2002 and a PhD in Clinical Research and Nursing from Case Western Reserve University in 2014. Dr. Faiman holds an advanced oncology nurse certification through ONCC. She is currently employed as an Adult Nurse Practitioner in the department of Hematology and Medical Oncology at the Cleveland Clinic in Cleveland, Ohio. She received the 2012 Excellence in Medical Oncology and 2013 Commendation for Patient and Nursing Education Award sponsored by The Oncology Nursing Society; and the 2015 Dean’s Legacy Award for PhD Studies from Case Western Reserve University and was named the Leukemia and Lymphoma Society’s Woman of the Year for Cleveland and Akron Ohio, 2016. She was appointed as a member of Case Comprehensive Cancer Center in 2020.
Dr. Faiman has become an exemplary leader in bringing critical knowledge in cancer nursing to providers- locally, nationally and internationally. She has established herself as an internationally renowned expert in cancer nursing through research, publications, and presentations; and as a mentor to nurses. Faiman edited the first bone marrow transplant nurse’s certification manual and co-edited the only myeloma nursing textbook. She authored 16 book chapters, 10 research papers, and 47 peer-reviewed papers. Faiman led the development of international myeloma nurse management guidelines and influenced cancer care practice by presenting at 26 international and 256 US national/regional conferences; including as lecture chair of 4 international and 66 national conferences.
Dr. Faiman remains an active author, presenter, and educator on the topic of multiple myeloma, amyloidosis, chronic lymphocytic leukemia, plasma cell dyscrasias, oncologic emergencies, as well as management of skeletal and other cancer complications. In 2006 she became a founding member of the International Myeloma Foundation Nurse Leadership Board and in 2019 appointed to the Hematology Specialty Board (HSB) in the American Board of Internal Medicine. Faiman is currently Editor-in-Chief of Journal of the Advanced Practitioner in Oncology (JADPRO), and founding Editor-in-Chief of The Oncology Nurse APN/PA and on the editorial board of ASH Clinical News among others.
Describe the burden of multiple myeloma in the US
Apply current best practices for myeloma assessment based on current standards and emerging advances
Select optimal treatment for multiple myeloma based on current guideline recommendations and expert opinion regarding emerging data
Summarize the latest developments in myeloma treatment that have changed management options for patients with myeloma
Devise treatment plans for multiple myeloma with consideration for age/frailty and other patient and disease characteristics


This activity has been designed to meet the educational needs of nurse practitioners (NPs), physician assistants (PAs) and oncology nurse specialists who manage patients with multiple myeloma.


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Horizon CME and Real CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

Horizon CME designates this enduring material activity for a maximum of  0.25 AMA PRA Category 1 Credits™. Physician should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME.

The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. Upon completion, NPs and RNs will be awarded up to 0.25 contact hours and 0.0 pharmacology hours.


Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members' relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.



Pam Dudkiewicz  has served on a Speakers Bureau for Celegene, Seattle Genetics, AstraZeneca and Rigel Pharmaceuticals. She has served on an Advisory Board for AstraZeneca.

Beth Faiman was a consultant for Celegene and Karyopharm.
Kevin Brigle has served on a Speakers’ Bureaus for AbbVie, Amgen, AstraZeneca, Celgene, Incyte, Karyopharm, Sanofi, and Takeda.

Other Contributor/Planner Disclosures
Additional non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.


Supporter Acknowledgement 

This activity is supported by an educational grant from Sanofi Genzyme, Karyopharm, and Janssen Biotech, Inc.



Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.